Expert Interview
A Second Look: Discussing Recent Clinical Data on Jazz Pharmaceuticals' Xywav and Avadel's LUMRYZ (sodium oxybate) for the Treatment of Narcolepsy
Ticker(s): AVDL, JAZZInstitution: Stanford
- Clinical Associate Professor, Neurology & Neurological Sciences & Clinical Associate Professor, Psychiatry and Behavioral Sciences - Sleep Medicine at Stanford.
- Manages 40 patients with narcolepsy and has prescribed SUNOSI.
- Research interests involve biomarkers of disease progression in REM sleep behavior disorder, and mechanisms and treatment of Postural Tachycardia Syndrome and Post-Acute COVID Syndrome; special interest in Autonomic Disorders, Sleep Disorders, and the interaction between these conditions.
What did you think about the primary findings of the TENOR study regarding the reasons patients utilized a Xywav individualized dosing regimen?
Added By: max_adminHow does the sodium content in Xywav compare to that in Xyrem in terms of the American Heart Association's daily ideal sodium intake for most adults?
Added By: max_adminCan you please comment on the baseline mean systolic blood pressure measurements for patients with narcolepsy and idiopathic hypersomnia in the exploratory, post-hoc analysis from two Phase 3 trials of Xywav?
Added By: max_adminHow does the sodium burden reduction from low-sodium therapies like Xywav impact the health risks in patients with sleep disorders?
Added By: max_adminCan you comment on the percentage of patients in the TENOR study reported benefiting from individualized dosing, and the most common reasons cited for taking a higher first dose?
Added By: max_adminHow does LUMRYZ differ from other sodium oxybate treatments in terms of dosing frequency?
Added By: max_adminWhat percentage of patients with narcolepsy experience poor, fragmented sleep, as mentioned in the data?
Added By: max_adminWhat's your impression on the key findings from the post-hoc analyses of the REST-ON trial regarding the improvement in EDS as measured by the Epworth Sleepiness Scale?
Added By: max_adminHow does the once-at-bedtime formulation of LUMRYZ impact the need for middle-of-the-night oxybate doses?
Added By: max_adminWhat insights did the RESTORE study provide regarding the long-term tolerability and symptom improvement with LUMRYZ in real-world use?
Added By: max_adminHow does the sodium content in LUMRYZ compare to other treatments in terms of its impact on cardiovascular health?
Can you comment on the primary outcomes of the REST-ON clinical trial that supported the FDA approval of LUMRYZ?
Added By: max_adminSince the FDA has declared LUMRYZ superior to all other oxybates on the market, are there any reasons why would you not have every patient, except those who have a cardiovascular issues , on LUMRYZ?
Will you be asking all your patients whether they would prefer a once nightly dosing?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
